-
Views
-
Cite
Cite
T. M. File, L. A. Mandell, G. Tillotson, Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study—authors' response, Journal of Antimicrobial Chemotherapy, Volume 60, Issue 4, October 2007, Page 903, https://doi.org/10.1093/jac/dkm333
Close - Share Icon Share
Extract
Sir,
We are in agreement with Dr Hammerschlag1 that assessment for Chlamydophila pneumoniae as an aetiology of respiratory infections is difficult; and we share her call for a consistent regulatory policy on acceptable criteria for determining microbiological efficacy. Since serological methods were the only means by which an atypical aetiology was assessed in our paper, we acknowledge this as a potential limitation, but felt that we should include this information to give the reader some impression of the pattern of aetiological agents found in our cases.
We would like to stress that the primary purpose of our paper was to demonstrate the clinical efficacy of a shorter 5 day course of gemifloxacin therapy for mild-to-moderate community-acquired pneumonia with the possible benefits which may accrue. We feel that we have demonstrated this in our paper.2
Transparency declarations
T. M. F. has received recent research funding from Abbott, Arpida AG, AstraZeneca, Bristol–Myers Squibb, Bayer, Binax Incorporated, Cubist, Genzyme, GlaxoSmithKline, Ortho-McNeil, Oscient, Pfizer, Sanofi-Aventis and Wyeth, is a consultant to Sanofi-Aventis, Bayer, GlaxoSmithKline, Ortho-McNeil, Merck, Oscient, Pfizer and Wyeth and is on the Speakers' Bureau of Abbott, Sanofi-Aventis, GlaxoSmithKline, Merck, Ortho-McNeil, Oscient, Pfizer, Schering Plough and Wyeth. Further, he does not own stocks in any company that might be financially affected by the conclusions of this article. L. A. M. has received research funding from Bayer, Pfizer, Sanofi-Aventis and Wyeth, is a consultant to AstraZeneca, Aventis, Bayer, Pfizer, Sanofi-Aventis and Wyeth and is on the Speakers' Bureau of Aventis, Bayer, Oscient, Pfizer and Sanofi-Aventis. G. S. T. was an employee of Oscient Pharmaceuticals at the time of the study and is currently an employee of Replidyne Pharmaceuticals, Louisville, CO, USA.
